Fundamental Data for SGEN

SEATTLE GE(NSDQ:SGEN)

Seatlle Genetic develops monoclonal antibody-based drugs to treat cancer and related diseases. Using its monoclonal antibody-based technologies and its expertise in cancer, the company have assembled a portfolio of drug candidates targeted to many types of human cancers. The company utilizes its monoclonal antibody-based technologies to increase the potency and efficacy of antibodies with specificity for cancer. The company is testing our two most advanced product candidates, SGN-15 and SGN-10, in patients with breast, colon, prostate or other cancers.

# Employees: 261

Address: 21823 30th Drive SE,Bothell,WA,USA

Phone: 425 527-4000

Fax: 425 527-4001

Website: www.seattlegenetics.com

Email: contact@seagen.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Clay B. Siegall (Presi.; C.E.O.)

Todd E. Simpson (C.F.O.; Princ. Acctg. Off.)

Franklin M. Berger (Dir.)

David W. Gryska (Dir.)

Clay B. Siegall (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/4/2010

Mean EPS (Next Qtr): ($0.25)

Mean EPS (Year): ($1.05)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 9

Shares Performance

Period	SGEN	Compare to S&P
YTD	4.03 %	-13.90 %
4 Weeks	-4.42 %	-5.45 %
12 Weeks	-23.71 %	-28.07 %

Shares Information

Analyst Coverage: Y

Avg Volume: 562102

Shares Outstanding: 97M

Market Cap: $0.91B

52 Week High: $14.80

52 Week Low: $7.23

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 SGEN split by factor of 1.250

Earnings Performance

EPS Growth in Last Quarter: 19.23 %

EPS Growth in Last Year: 22.22 %

Sales Growth in Last Quarter: 23.79 %

Sales Growth in Last Quarter: 44.15 %

Financials

Qtr Book Value: $4.22

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 22.610